Neutral
Becton Dickinson reported strong Q2 fiscal 2026 results with revenue reaching $5.2 billion, a 4.7% increase year-over-year, and adjusted EPS up 8.2% t...
Becton Dickinson (BDX) has experienced prolonged share price weakness, with its stock broadly flat over the last month and down significantly year-to-...
Bullish
Becton Dickinson (BD) offers investors a defensive edge in the healthcare sector through its diversified portfolio of diagnostics, devices, and pharma...
Neutral
Becton, Dickinson and Company (BDX) is expanding its portfolio with higher-value, clinically differentiated devices like the PureWick Urine Collection...
Bullish
Becton Dickinson (BDX) reported strong third-quarter 2025 results, with sequential growth improvements and adjusted diluted EPS of $3.68, surpassing e...
Neutral
This article analyzes Cooper Companies (NASDAQ:COO) and Becton, Dickinson and Company (NYSE:BDX), two major medical device companies, comparing them o...
Neutral
Becton Dickinson (NYSE:BDX) is managing the upcoming retirement of Richard Byrd, head of its Interventional Segment, while simultaneously pursuing CE ...